Solana Co (HSDT) Earnings History

HELIUS MEDICAL TECHNOLOGIES, INC. - Q3 FY2025 Earnings

Filed at: Nov 18, 2025, 4:20 PM EST|Read from source

EXECUTIVE SUMMARY

Solana Company reported significant financial activity in Q3 2025, driven by a large capital raise and the launch of its digital asset treasury strategy, alongside progress in its neurotech business. The company experienced substantial growth in assets and liabilities due to these strategic initiatives.

POSITIVE HIGHLIGHTS

  • •

    Closed partnership with Pantera Capital and Summer Capital for over $500 Million in funding.

    positive
  • •

    Issued cash-exercise warrants for a potential aggregate $750M additional capital raise.

    positive
  • •

    Announced positive clinical data demonstrating PoNS superior effectiveness in improving gait deficit.

    positive
  • •

    Submitted FDA 510(k) designation for PoNS® Device Label Expansion in Stroke.

    positive
  • •

    Launched ATM program and approved a stock repurchase program for up to $100 million.

    neutral
  • •

    Revenue increased significantly to $697,000 from $51,000 in the prior year period, including first-time staking rewards income.

    positive

CONCERNS & RISKS

  • •

    Reported a net loss of $352.8 million, a substantial increase from a net loss of $3.7 million in the prior-year period.

    negative
  • •

    Loss per basic and diluted common share was $32.89, compared to a loss of $744.35 in the prior-year period, reflecting significant dilution.

    negative
  • •

    Total operating expenses increased to $36.0 million from $3.9 million in the prior year period.

    attention
  • •

    Significant non-operating loss of $317.3 million, including a large loss on derivative liability and financing costs from the PIPE transaction.

    negative

FINANCIAL METRICS

Revenue
Quarterly
$697.00K
+1266.7%
Prior year: $51.00K
Annual (YTD)
$789.00K
N/A
Prior year: $368.00K
Net Income
Quarterly
$-352.77M
N/A
Prior year: $-3.69M
Annual (YTD)
$-366.44M
N/A
Prior year: $-7.81M
EPS (Diluted)
Quarterly
$-32.89
N/A
Prior year: $-744.35
Annual (YTD)
$-90.14
N/A
Prior year: $-2507.81
Operating Income
Quarterly
$-35.45M
N/A
Prior year: $-4.07M
Annual (YTD)
$-42.78M
N/A
Prior year: $-10.76M
EPS (Basic)
Quarterly
$-32.89
N/A
Prior year: $-744.35
Annual (YTD)
$-90.14
N/A
Prior year: $-2507.81

MARGIN ANALYSIS

Gross Margin
Current Quarter
85.2%
Prior Year
-266.7%
YoY Change
+1119 bps
Operating Margin
Current Quarter
-5086.1%
Prior Year
-8000.0%
YoY Change
+2914 bps
Net Margin
Current Quarter
-50612.4%
Prior Year
-72274.5%
YoY Change
+21662 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

SPECIAL ITEMS & ADJUSTMENTS

Q3 2025
Unrealized loss on digital assets
Reflects changes in fair value of digital assets held.
+$30.54M
Q3 2025
Loss on derivative liability
Attributable to the valuation of stapled warrants from the September PIPE transaction.
+$545.73M
Q3 2025
Financing costs from September PIPE transaction
Includes non-cash charges for advisory warrants and shares issued to Clear Street.
+$194.74M
Q3 2025
Gain from change in fair value of related derivative liability
Offsetting the loss on derivative liability from stapled warrants.
+$423.31M
Total Impact
+$1,194.32M

Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.

MANAGEMENT COMMENTARY

Solana Company's digital treasury strategy and recent PIPE transaction are significant milestones.

— HELIUS MEDICAL TECHNOLOGIES, INC., Q3 FY2025 2025 Earnings Call

Positioned to accelerate growth and drive value with support from Pantera and Summer Capital.

— HELIUS MEDICAL TECHNOLOGIES, INC., Q3 FY2025 2025 Earnings Call

Achieved notable progress across advocacy, capital markets, and treasury management.

— HELIUS MEDICAL TECHNOLOGIES, INC., Q3 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

PoNS Effectiveness
N/A
clinical data
Staking Rewards Income
342.0K
dollars

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.